Kuan-Yu Tseng

Kuan-Yu Tseng

Auto-generated profile, based on publicly available information

Kuan-Yu Tseng

Division of Medical Oncology, Department of Oncology, Taichung Veterans General Hospital, Taichung, Taiwan

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 September 2025 in Therapeutic Advances in Medical Oncology
Verified
Journal Article
Open access
Hsin-Chen LinHsin-Chen Lin
Hsin-Chen Lin
KTKuan-Yu Tseng
Kuan-Yu Tseng
YSYu-Hsuan Shih
Yu-Hsuan Shih
Background: Gallbladder cancer (GBC) represents a rare but aggressive malignancy, often diagnosed at an advanced stage. Although immune checkpoint inhibitors have improved outcomes in biliary tract cancers, GBC-specific evidence remains limited due to underrepresentation in pivotal clinical trials. Objectives: To evaluate the real-world effectiveness and safety of durvalumab combined with gemcitabine and cisplatin (Durva + gemcitabine and cisplatin (GemCis)) compared to GemCis alone in patients with advanced GBC. Design: Retrospective, multi-institutional cohort study. Methods: Data were collected from the TriNetX Global Collaborative Network. Adults diagnosed with advanced GBC between January 2020 and January 2025 who received Durva + GemCis or GemCis as first-line therapy were included. Propensity score matching (1:1) was performed based on age, sex, race, metastatic sites, and tumor marker levels. The primary outcome was overall survival (OS), whereas secondary outcomes included adverse events (AEs). Results: Among 2458 patients with advanced GBC, 130 received Durva + GemCis and 201 received GemCis. After matching, 111 patients per group were analyzed. Median OS was significantly longer in the Durva + GemCis group compared to the GemCis group (13.1 vs 8.5 months; log-rank p = 0.028). Most AEs were comparable between groups; however, malaise and fatigue were more frequently reported in the Durva group (28.8% vs 16.2%; hazard ratio: 1.98, 95% confidence interval: 1.11–3.53). Conclusion: In this real-world study, the addition of durvalumab to GemCis was associated with improved OS in patients with advanced GBC, with a manageable safety profile. These exploratory findings should be interpreted with caution, underscoring the need for dedicated GBC-specific prospective trials.

21 February 2026 in Therapeutic Advances in Medical Oncology
Verified
Journal Article
Open access
KTKuan-Yu Tseng
Kuan-Yu Tseng
CHChiann-Yi Hsu
Chiann-Yi Hsu
CWCheng-Han Wu
Cheng-Han Wu
YSYu-Hsuan Shih
Yu-Hsuan Shih
Hsin-Chen LinHsin-Chen Lin
Hsin-Chen Lin
Background: Pancreatic adenocarcinoma is one of the leading causes of cancer-related mortality. The median overall survival (OS) of patients with advanced pancreatic ductal adenocarcinoma (PDAC) is less than 1 year. The recent phase III NAPOLI-3 study showed that triplet chemotherapy improved OS compared to the commonly used gemcitabine/nab-paclitaxel (GA) regimen. S-1 is widely used in Asia for the treatment of PDAC, and a combination strategy with S-1 has shown encouraging results in previous studies. Objectives: We aimed to determine whether the addition of S-1 to GA offers more benefits than GA alone as a first-line treatment for advanced PDAC. Design: This was a retrospective study of patients with advanced PDAC treated at the Taichung Veterans General Hospital, Taiwan. All patients received first-line GA-based therapy, including GA alone or GA in combination with S-1 (GAS). Methods: Retrospectively reviewed clinical characteristics and outcomes, including the objective response rate (ORR), progression-free survival (PFS), and OS, were compared between the two groups. Some patients underwent genetic testing using the FoundationOne CDx (Foundation Medicine). The effects of the treatment on major genetic alterations were also analyzed. Results: Between January 1, 2022, and February 10, 2025, 89 patients were enrolled. Among these, 45 and 44 underwent GA and GAS, respectively. The median follow-up time was 10.2 months. ORR was significantly higher in patients who received GAS than in those who did not (48% vs 18%, p = 0.001). GAS showed both significant improvement of PFS (10.0 vs 5.2 months; p = 0.004) and OS (not reached vs 8.5 months; p = 0.016) compared with GA. Multivariate analysis identified only the treatment regimen as an independent prognostic factor for OS. GAS also improved the survival of patients harboring major genetic alterations. The Grade ⩾3 hematological adverse events were more in GAS, according to the CTCAE, version 5.0. No treatment-related mortality was found. Conclusion: The S-1 could be combined with GA as another potential triplet combination treatment option for advanced PDAC.

7 October 2026 in The Oncologist
Verified
Journal Article
Open access
CCChun-Yang Chao
Chun-Yang Chao
KTKuan-Yu Tseng
Kuan-Yu Tseng
Hsin-Chen LinHsin-Chen Lin
Hsin-Chen Lin
YSYu-Hsuan Shih
Yu-Hsuan Shih
Background: Advanced biliary tract cancer (BTC) has a poor prognosis following progression on first-line gemcitabine plus cisplatin. However, evidence comparing second-line chemotherapy regimens remains limited. This study aimed to compare the effectiveness and safety of fluorouracil, leucovorin, and oxaliplatin (FOLFOX); fluorouracil, leucovorin, and irinotecan (FOLFIRI); and capecitabine plus oxaliplatin (CapOx). Patients and Methods: Adults with advanced BTC who received first-line gemcitabine plus cisplatin followed by second-line FOLFOX, FOLFIRI, or CapOx between January 2010 and July 2025 were identified from the TriNetX Global Collaborative Network. Patients who subsequently received molecularly targeted therapies were excluded. The study included 825 patients receiving FOLFOX, 184 receiving FOLFIRI, and 149 receiving CapOx; after 1:1 propensity score matching, the respective comparisons included 182 and 149 patients per group. Overall survival (OS) and treatment-related adverse events were compared between the matched cohorts. Results: The median OS was comparable between FOLFOX and FOLFIRI (5.7 months vs 5.8 months, P = .958) and between FOLFOX and CapOx (5.7 months vs 5.8 months, P = .803). The overall adverse event profiles were also comparable. However, FOLFOX was associated with lower rates of neutropenia but higher rates of thrombocytopenia than FOLFIRI. In contrast, FOLFOX and CapOx demonstrated similar toxicity despite modest differences in anemia and thrombocytopenia. Conclusion: This real-world study demonstrates comparable survival outcomes among FOLFOX, FOLFIRI, and CapOx as second-line chemotherapies for advanced BTC. These findings support individualized regimen selection based on patient characteristics and toxicity profiles.